The Lavipharm Group's adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations for the first nine months of 2024 increased by 21.2% to €9.08 million compared to €7.55 million in the corresponding period of the previous year.

Similarly, total adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to €9.42 million compared to €7.47 million, representing an increase of 26.1%. We recall that expenses have been charged by an amount of €1.02 million, which is the non-cash (accounting) representation attributable to the period and relates to the valuation of the stock award plan and stock option plan.

Consolidated sales before clawbacks & rebates amounted to €47.38 million compared to €40.85 million in the same period last year, a double-digit increase of 16.0%.

The gross profit for the Nine Months 2024 amounted to €19.89 million compared to €16.35 million in the corresponding period of 2023, significantly improving by 21.6%.

Consolidated profit before tax from continuing operations amounted to €4.28 million compared to the amount of €2.83 million in the nine months of 2023, showing a significant increase of 51.3%.

Total Profit after Taxes amounted to €9.22 million compared to €2.10 million in Nine Months 2023, showing an explosive increase of 338.6% due to the recognition of a deferred tax asset resulting from the Group's decision to liquidate subsidiaries that had previously accumulated significant losses.

The Lavipharm Group's net debt as of 30/09/2024 amounted to €26.04 million.

In terms of sales, the export segment shows an increase of 11.4%. In the domestic market, and due to the recent acquisitions, sales of prescription drugs are up by 28.0% and non-prescription drugs (OTC) by 13.8%. The group's other sales, which represent 4.8% of total turnover and relate to ancillary activities, recorded a decrease of 18.5%.